Securities code: 688767 securities abbreviation: Hangzhou Biotest Biotech Co.Ltd(688767) Announcement No.: 2022-005 Hangzhou Biotest Biotech Co.Ltd(688767)
Announcement on correction of annual performance increase in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
1、 Performance forecast of the current period
(I) performance forecast period
From January 1, 2021 to December 31, 2021.
(II) performance forecast
1. According to the preliminary calculation of the financial department, it is estimated that the net profit attributable to the owners of the parent company will reach 810 million yuan to 910 million yuan in 2021, an increase of 374.8533 million yuan to 474.8533 million yuan, an increase of 86.14% to 109.12% year-on-year compared with the same period of the previous year (legally disclosed data).
2. The net profit attributable to the owner of the parent company after deducting non recurring profits and losses is 802185300 yuan to 902185300 yuan, which will increase by 372529800 yuan to 472529800 yuan, an increase of 86.70% to 109.98% year-on-year compared with the same period of the previous year (legally disclosed data).
(III) this performance forecast has not been audited by certified public accountants.
2、 Performance in the same period of last year
Net profit attributable to the owner of the parent company: 435146700 yuan.
Net profit attributable to the owner of the parent company after deducting non recurring profits and losses: 429655500 yuan.
3、 Main reasons for performance changes in the current period
(I) main business impact:
During the reporting period, the global COVID-19 epidemic is still continuing. The company continues to fully support the global epidemic prevention and control. In the first half of 2021, the company developed New Coronavirus antigen detection kit in the international market, and achieved good sales results. In the second half of the year, the New Coronavirus antigen family self testing kit developed by the company has won the CE certification of the European Union. Australian TGA certification, affected by covid-19 virus Delta, Omicron and other mutated viruses, the number of covid-19 infection cases in Europe, Australia and other countries and regions continued to increase significantly, the demand for covid-19 antigen detection reagents increased significantly, and the company’s overseas covid-19 detection reagent orders and revenue increased significantly, As a result, the sales performance in 2021 increased significantly compared with the same period last year.
(II) other impacts: there are no non recurring profits and losses, accounting treatment and other major factors. 4、 Risk tips
1. The company has no uncertain factors affecting the accuracy of the performance forecast, and the performance forecast has not been audited by certified public accountants.
2. Whether the company’s future sales performance can continue to maintain a significant growth trend is uncertain, which is affected by many factors, such as overseas epidemic development and epidemic prevention and control policies, market competition, path selection of international epidemic on technical products, product competitiveness and channel ability of the company, customer recognition and so on, The sales and profit contribution of the above covid-19 products are uncertain. Please pay attention to the investment risk. 5、 Other explanatory matters
The above forecast data are only preliminary accounting data. The specific and accurate financial data shall be subject to the audited annual report of 2021 officially disclosed by the company. Please pay attention to the investment risks.
It is hereby announced.
Hangzhou Biotest Biotech Co.Ltd(688767) board of directors January 15, 2022
